Q3 EPS Estimate for Aprea Therapeutics Raised by Analyst

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Investment analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for shares of Aprea Therapeutics in a research report issued to clients and investors on Wednesday, August 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.09) per share for the quarter, up from their prior forecast of ($0.23). The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.39) EPS.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Wednesday, August 12th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.11. Aprea Therapeutics had a negative return on equity of 56.85% and a negative net margin of 4,405.59%.

Several other brokerages have also recently commented on APRE. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Friday, July 17th. Wedbush cut their price target on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Oppenheimer initiated coverage on shares of Aprea Therapeutics in a research note on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price objective for the company. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Aprea Therapeutics currently has a consensus rating of “Hold” and an average target price of $3.07.

Aprea Therapeutics Trading Down 1.8%

Shares of APRE opened at $0.67 on Friday. The business’s 50-day moving average price is $0.71 and its 200 day moving average price is $0.77. The stock has a market capitalization of $8.31 million, a P/E ratio of -0.62 and a beta of 1.52. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.79.

Institutional Investors Weigh In On Aprea Therapeutics

Institutional investors have recently bought and sold shares of the business. DRW Securities LLC acquired a new position in shares of Aprea Therapeutics in the 4th quarter valued at about $103,000. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics during the 4th quarter valued at $40,000. Finally, AIGH Capital Management LLC increased its stake in shares of Aprea Therapeutics by 174.1% in the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after acquiring an additional 645,000 shares during the last quarter. 34.19% of the stock is currently owned by institutional investors and hedge funds.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.